Document Detail


Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival.
MedLine Citation:
PMID:  8833409     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We assessed the efficacy and toxicity of interferon alpha 2b (IFN) as maintenance therapy in patients with low grade malignant lymphoma. Between March 1986 and December 1989, 98 patients with low-grade malignant lymphoma in complete remission after conventional chemotherapy were randomly assigned to received IFN, 5.0 MU three times a week for one year, as maintenance therapy (n = 48), or to receive no treatment (control group, n = 50). In March 1994, the median duration of response had not yet been reached in the patients treated with IFN compared to 46 months in the control group. At 9-years 62% of the patients in the IFN arm remain in first complete remission compared to only 25% in the control group (p <.001). In addition, the median duration of survival has not yet been reached in either the IFN arm compared to 74 months in the control group (p <.001). Quality of life was excellent in both groups and severe side effects secondary to IFN treatment were not observed. All patients completed the planned dose of IFN. We conclude that IFN as maintenance therapy in low-grade malignant lymphoma is an excellent therapeutic option because it improves the duration of remission and survival without producing severe side effects or reducing the quality of life.
Authors:
A Aviles; G Duque; A Talavera; R Guzman
Related Documents :
21520159 - The association between pre-operative psa and prostate cancer-specific mortality in pat...
17215529 - Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
2213099 - Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignan...
4080299 - Phase i study of recombinant human interferon alpha-2c in patients with chemotherapy-re...
7834119 - Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lym...
18501079 - Phase ii trial of pegylated interferon-alpha 2b in patients with advanced renal cell ca...
21518379 - Incidence and survival of desmoplastic melanoma in the united states, 1992-2007.
15041219 - Detection of t(14;18) in follicular lymphoma by dual-color fluorescence in situ hybridi...
9250019 - In vivo cell kinetics in elderly patients affected by squamous cell carcinoma of the he...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  20     ISSN:  1042-8194     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  1996 Feb 
Date Detail:
Created Date:  1997-06-12     Completed Date:  1997-06-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  495-9     Citation Subset:  IM    
Affiliation:
Department of Hematology, Oncology Hospital, National Medical Center, Mexico.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bleomycin / administration & dosage
Combined Modality Therapy
Cyclophosphamide / administration & dosage
Disease-Free Survival
Epirubicin / administration & dosage
Female
Humans
Immunologic Factors / therapeutic use*
Interferon Alfa-2b / therapeutic use*
Life Tables
Lymphoma, Non-Hodgkin / drug therapy*,  mortality
Male
Middle Aged
Patient Acceptance of Health Care
Prednisone / administration & dosage
Quality of Life
Remission Induction
Survival Analysis
Treatment Outcome
Vincristine / administration & dosage
Chemical
Reg. No./Substance:
0/CEOP-B protocol; 0/COP protocol 2; 0/Immunologic Factors; 11056-06-7/Bleomycin; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 56420-45-2/Epirubicin; 57-22-7/Vincristine; 99210-65-8/Interferon Alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rotenone, a mitochondrial NADH dehydrogenase inhibitor, induces cell surface expression of CD13 and ...
Next Document:  Chronic lymphocytic leukaemia with upper airway obstruction.